Jobes Michelle L, Aharonovich Efrat, Epstein David H, Phillips Karran A, Reamer David, Anderson Micheline, Preston Kenzie L
Clinical Pharmacology and Therapeutics Research Branch, Intramural Research Program of the National Institute on Drug Abuse, Baltimore, MD (M.L.J., K.A.P., D.R., M.A., K.L.P.); and Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York, NY (E.A.).
J Addict Med. 2015 Nov-Dec;9(6):491-8. doi: 10.1097/ADM.0000000000000169.
Relapse to drug misuse may follow exposure to drug cues that elicit craving. The learned associations, or "emotional memories," that underlie responses to cues may be attenuated or erased by the β-adrenergic antagonist propranolol during a "reconsolidation window" shortly after the memories are reactivated by cues.
We evaluated the effects of propranolol on cue-induced drug cravings in healthy opioid-dependent individuals who used cocaine while receiving methadone maintenance (n = 33). Participants were asked to recall specific cocaine use and neutral events in an interview; these events were used to develop personalized auditory script/cue sets. Approximately 1 week later, propranolol (40 mg) or placebo (random assignment, double blind) was administered orally before presentation of the script/cue sets; the presentation of the script/cue sets were tested 1 week and 5 weeks after the propranolol/placebo session. Ongoing drug use was monitored via urine screens and self-report in twice-weekly visits.
Cue reactivity, as assessed by craving scales and physiological responses, was unexpectedly greater in the propranolol group than in the placebo group. This counterhypothesized group difference was present acutely during propranolol administration and seemed to persist (without reaching statistical significance) during the subsequent test sessions.
Our results do not support the use of propranolol for cue-induced cocaine craving in opioid-maintained patients.
接触引发渴望的药物线索后可能会出现药物滥用复发。在记忆被线索重新激活后的“重新巩固窗口期”,β-肾上腺素能拮抗剂普萘洛尔可能会减弱或消除作为对线索反应基础的习得性关联或“情绪记忆”。
我们评估了普萘洛尔对在接受美沙酮维持治疗时使用可卡因的健康阿片类药物依赖个体中线索诱导的药物渴望的影响(n = 33)。参与者被要求在访谈中回忆特定的可卡因使用和中性事件;这些事件被用于开发个性化的听觉脚本/线索集。大约1周后,在呈现脚本/线索集之前口服普萘洛尔(40毫克)或安慰剂(随机分配,双盲);在普萘洛尔/安慰剂疗程后1周和5周对脚本/线索集的呈现进行测试。通过尿液筛查和每周两次访视中的自我报告来监测持续的药物使用情况。
通过渴望量表和生理反应评估的线索反应性,普萘洛尔组意外地高于安慰剂组。这种与假设相反的组间差异在普萘洛尔给药期间急性出现,并且在随后的测试疗程中似乎持续存在(未达到统计学显著性)。
我们的结果不支持在阿片类药物维持治疗的患者中使用普萘洛尔来治疗线索诱导的可卡因渴望。